Global Oncology Based In-Vivo CRO Market - 2021-2028
The global oncology based in-vivo CRO market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
The oncology-based In-Vivo CRO gives preclinical drug development, testing, and infection examination research in oncology. The demand for research organizations in the In-Vivo contract has been increasing. Pharmaceutical companies have been building their pipeline drugs to create and construct new molecules to retain substantial benefits and patent products in the marketplace.
The major factors driving the growth of this market are the increasing numbers of cancer patients, accessibility to government investment for R&D services, and increasing knowledge regarding cancer by CROs.
Surge in the aging population prone to chronic diseases will drive the market growth
An increase in the geriatric population has also been driving the growth of the oncology-based In-Vivo CRO market. With the growing number of specific therapies in the oncology pipeline and the presence of a large fraction of pipeline drugs, the number of late-stage pipeline treatments rose from 711 in 2017 to 849 in 2018, an increase of 19%, and the use of oncology based In-Vivo CRO help in deriving the novel therapies for the prevention, diagnosis and treatment to patients.
As per Global Health and Aging report published by the World Health Organization, the number of people aged 65 years or greater is expected to increase from a predicted 524 million in 2010 to about 1.5 billion by 2050, with a significant percentage of increase in emerging economies. Primary chronic diseases such as cancer have had the most significant impact on the geriatric population, especially in high-income countries, which are further expected to boost the market growth.
Increasing adoption of smartphones and tablets along with preference for mobile payments is driving the market growth
The massive use of smartphones in the healthcare and pharma sectors and growing internet & social media penetration across the globe is expected to facilitate the emergence of the oncology-based in-vivo CRO industry over the forecast period. Along with preference for mobile payments has also positively impacted the growth and increased preference to shop without interacting with sales representatives, which is anticipated to drive the market in the forecast period.
Furthermore, the pressure from the increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling the pharmaceutical companies to aid such organizations will drive the oncology-based in-vivo CRO market growth over the forecast period.
Lack of funds for research will hamper the market growth in the forecast period
However, the govt and other research organizations understand the lean towards higher spending in clinical studies over preclinical, which eventually led to a better failure rate. Additionally, the lack of funds for the research activities, mostly in the developing countries, is also hampering the market growth in the forecast period.
COVID-19 Impact Analysis
Several months into the COVID-19 pandemic, professionals in most industries hold their work. The Oncology Based In-Vivo CRO industry is no exception. Research firms and clients alike fret over having to pause or cancel studies. They are interested in solutions that may help keep their essential work moving. CROs report that an approximate 40% decrease in new clinical trials starts for the first part of the year and expect it to continue; they also appeared motivated to pursue solutions that keep their work moving during obstacles created by the pandemic. These factors will hamper the market growth in the forecast period.
Blood Cancer segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
As per the Bristol-Myers Squibb Company report, above 1.85 million new blood cancer cases are anticipated to be diagnosed across the globe in 2040, in which 918,872 cases are from lymphoma, 275,047 cases myeloma and 656,345 from leukemia. Furthermore, the report predicted, in 2040, the estimated number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, higher than 387,000 people lived with leukemia in the U.S., and an expected 68,000 deaths will result from blood cancer. As per the national cancer institute, the expected deaths due to blood cancer are about 22,840 in 2019. The escalating deaths and rising incidence of blood cancer cases globally drive the market.
Patient Derived Xenograft (PDX) segment are expected to dominate the Oncology Based In-Vivo CRO Market, by model, during the forecast period
PDX mice models are the most commonly adopted approaches for confirming the results collected in the in-vivo studies of cancer drug candidates. The preclinical studies for cancer are driven through a personalized approach, which is the current trending therapy. GuizhongLui of Crown Bioscience, Inc. published a document stating the benefits of using a Patient-Derived Xenograft (PDX) model in mice.
Currently, cancer is a vital burden on the healthcare systems. As per the data released by GLOBOCAN in 2020, it is estimated that 19.3 million cases and 10 million cancer deaths occurred in 2020. In vitro and in vivo strategies are being developed to combat the rising prevalence of cancer and offer effective treatments to patients. A significant development in this regard is the emergence of PDX models, as they have high predictive power for the efficacy of standard and novel anti-cancer therapeutics. Owing to this advantage, these models are increasingly being used in preclinical studies.
For instance, in 2019, Charles River Laboratories (US) updated its online Tumor Model Compendium by adding 79 new patient-derived xenografts, ten new cell line-derived xenografts, and 36 new cell line models for several cancer types, including anal, colon, lung, and renal cancer, as well as leukemia and melanoma.
North America region holds the largest market share in the global oncology based in-vivo CRO market
North America region dominates the global oncology based in-vivo CRO Market accounted for the largest market share in 2020, owing to the rising prevalence of cancer, the availability of advanced healthcare infrastructure, and the presence of a large number of CROs in the region among the significant factors. In the North American region, the United States holds the largest market share, owing to the factors, such as the increasing population suffering from cancer, along with the rising geriatric population and research and developments related to cancer therapy and rising government initiative for the awareness of cancer in the country.
The availability of significant investments in this region is likely to impact the research activities ultimately. In addition, major life science and pharmaceutical companies which are majorly involved in drug improvement are present in this region. Owing to the well-planned funding and favorable regulatory policies, the global oncology based in-vivo CRO market in this region is expected to drive the market growth.
The oncology based in-vivo CRO market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Crown Bioscience, Charles River Laboratory, ICON Plc. Eurofins Scientific, Taconic Biosciences, Covance, Boji Pharmaceutical, Hunan Kailarui Biotech Co., Ltd., Xi'an Julong Bio-Tech Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oncology based in-vivo CRO market globally.
Oncology Based In-Vivo CRO Market Key Companies to Watch
Overview: Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in the areas of Oncology, Inflammation, and Metabolic Diseases. CrownBio provides preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models for the evaluation of CAR-T therapies, syngeneics, and humanized models.
Product Portfolio: The Company offers drug discovery and development services in the areas of Oncology, Inflammation, and Metabolic Diseases.
Why Purchase the Report?
• Visualize the composition of the oncology based in-vivo CRO Market segmentation by indication, model and end user highlighting the key commercial assets and players.
• Identify commercial opportunities in oncology based in-vivo CRO Market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of oncology based in-vivo CRO Market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players
The global oncology based in-vivo CRO Market report would provide an access to an approx. 61 market data table, 53 figures and 200 pages.
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
Global Oncology Based In-Vivo CRO Market - By Indication
• Blood Cancer
• Solid Tumors
Global Oncology Based In-Vivo CRO Market - By Model
• Patient Derived Xenograft (PDX)
Global Oncology Based In-Vivo CRO Market - By End User
• Research Organizations
• Pharmaceutical Companies
Global Oncology Based In-Vivo CRO Market - By Region
• North America
• South America
• Middle East & Africa
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook